ELI LILLY AND COMPANY Shareholders' Equity
ELI LILLY AND COMPANY (LLY) had Shareholders' Equity of $33.88 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $33.88B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $31.20B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $26.54B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $23.79B.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $33.88B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $31.20B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $26.54B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $23.79B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $18.27B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $15.76B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $14.27B 10-K · filed 2026-02-12 | $14.19B 10-K · filed 2025-02-19 |
| 2024-09-30 | $14.24B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $13.56B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $12.81B 10-Q · filed 2024-04-30 | |
| 2023-12-31 | $10.77B 10-K · filed 2025-02-19 | |
| 2023-09-30 | $11.22B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $11.06B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $11.19B 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $10.65B 10-K · filed 2024-02-21 | |
| 2022-09-30 | $10.07B 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $8.54B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $9.33B 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $8.98B 10-K · filed 2023-02-22 | |
| 2021-09-30 | $7.76B 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $6.44B 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $6.90B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $5.64B 10-K · filed 2022-02-23 | |
| 2020-09-30 | $4.83B 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $4.09B 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $3.08B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $2.61B 10-K · filed 2021-02-17 | |
| 2019-09-30 | $3.38B 10-Q · filed 2019-10-25 | |
| 2019-06-30 | $2.78B 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $2.48B 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $9.83B 10-K · filed 2020-02-19 | |
| 2018-09-30 | $13.08B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $11.56B 10-Q · filed 2018-07-25 | |
| 2018-03-31 | $14.53B 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $11.59B 8-K · filed 2019-10-24 | |
| 2017-09-30 | $14.89B 10-Q · filed 2017-10-27 | |
| 2017-06-30 | $14.10B 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $14.03B 10-Q · filed 2017-05-01 | |
| 2016-12-31 | $14.01B 10-K · filed 2018-02-20 | |
| 2016-09-30 | $15.59B 10-Q · filed 2016-10-28 | |
| 2016-06-30 | $14.64B 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $15.01B 10-Q · filed 2016-04-29 | |
| 2015-12-31 | $14.57B 10-K · filed 2018-02-20 | |
| 2015-09-30 | $15.22B 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $14.67B 10-Q · filed 2015-07-30 | |
| 2015-03-31 | $14.92B 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $15.37B 10-K · filed 2018-02-20 | |
| 2014-09-30 | $17.67B 10-Q · filed 2014-10-29 | |
| 2014-06-30 | $17.98B 10-Q · filed 2014-07-28 | |
| 2014-03-31 | $18.34B 10-Q · filed 2014-04-28 | |
| 2013-12-31 | $17.63B 10-K · filed 2017-02-21 | |
| 2012-12-31 | $14.77B 10-K · filed 2016-02-19 | |
| 2011-12-31 | $13.54B 10-K · filed 2015-02-19 | |
| 2010-12-31 | $12.42B 10-K · filed 2014-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |